Navigation Links
Endo Pharmaceuticals Reports Strong Fourth Quarter and Full-Year 2009 Financial Results: Provides 2010 Financial Guidance
Date:2/22/2010

r common share guidance $3.15 To $3.20 The company's guidance is being issued based on certain assumptions including: -- Adjusted effective tax rate of approximately 33% in 2010. -- Certain of the above amounts are based on estimates and there can be no assurance that Endo will achieve these results. -- Includes all completed business development transactions as of Dec. 31, 2009.

About Endo

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, prostate cancer, bladder cancer and the early onset of puberty in children, or central precocious puberty (CPP). Its products include LIDODERM®, a topical patch to relieve the pain of postherpetic neuralgia; Percocet® and Percodan® tablets for the relief of moderate-to-moderately severe pain; FROVA® tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA® tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA® ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; Voltaren® Gel, which is owned and licensed by Novartis AG, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as those of the hand
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... Calif. , July 27, 2015 Allergan ... (NASDAQ: KYTH ) today announced that the U.S. ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... acquisition of KYTHERA.  Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO ... of Allergan and KYTHERA filed a Pre-Merger Notification and ...
(Date:7/27/2015)... 2015   Mallinckrodt plc (NYSE: ... today that it has entered into a definitive ... contrast media and delivery systems (CMDS) business to ... at approximately $270 million.   Mallinckrodt,s ... with the company,s stated plan to strategically streamline ...
(Date:7/27/2015)... -- EnzymeBioSystems (OTC BB: ENZB - News) announces that a ... the Company,s lead pharmaceutical product. EnzymeBioSystems plans to seek ... prevention of breast cancer. "We are pleased ... has been completed," stated Gary Rojewski , CEO ... will allow us to move forward in beginning to ...
Breaking Medicine Technology:Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 2Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 3Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 4Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 5Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 6Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 7Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 8Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 9Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 2Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 3Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 4Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 5Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 6Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 7Amooranin Preclinical Sample Batch Completed 2
... Determine How Chest X-Ray CAD Could ... High-Tech Tool for Early Detection, Increased Patient ... and Riverain Medical,today announced the establishment of the ... chest X-ray CAD (computer-aided detection) can improve,practical early ...
... 26 CuraGen Corporation,(Nasdaq: CRGN ), a ... (Copenhagen Stock Exchange: TOPO) announced,today that updated preliminary ... belinostat for T-cell lymphomas, and new preclinical data,evaluating ... presented,at the 2007 American Society of Hematology (ASH) ...
Cached Medicine Technology:Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection 2Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection 3Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection 4Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection 5Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection 6Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection 7CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 2CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 3CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 4CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 5
(Date:7/27/2015)... , ... July 27, 2015 , ... ... especially in wound center management. Earlier this year Wound Care Advantage ... and training for WCA wound centers. Customized learning paths allow for clinicians, ...
(Date:7/27/2015)... ... 2015 , ... The heroin epidemic is affecting the Charlotte in North Carolina ... The rate for heroin usage has continued to climb around the country in part ... expensive alternative for those with an addiction to prescription opiate medications. According to WCNC, ...
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... ... From Step One, **FDAnews Webinar**, Aug. 13, 2015 — 1:30 p.m. – 3:00 ... one of the first things FDA investigators will look at during an inspection. ...
(Date:7/27/2015)... ... July 27, 2015 , ... The FSH ... and incurable disease, facioscapulohumeral muscular dystrophy (FSHD), today announced the introduction of the ... FSHD care guideline is published today. , This new guideline condenses the ...
(Date:7/27/2015)... CA (PRWEB) , ... July 27, 2015 , ... In ... a case for the personal side of plastic surgery and explained why people should ... “stop knocking cosmetic surgery for the excesses of the few and celebrate it for ...
Breaking Medicine News(10 mins):Health News:Wound Care Advantage Launches Luvo University An Online Hub For Wound Care Education and Training 2Health News:Wound Care Advantage Launches Luvo University An Online Hub For Wound Care Education and Training 3Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 2Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 3Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 2Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 3Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 4Health News:First-Ever FSHD Evidence-based Care Guideline Published by the American Academy of Neurology 2Health News:Recent Op-Ed Defending Plastic Surgery Highlights the Personal Side of Cosmetic Procedures, says Beverly Hills Physicians 2
... Duke University Medical Center have found that a ... cells could be a pioneering treatment for leukemias, ... cells are the main producers of antibodies, the ... uncontrolled production of these B cells is responsible ...
... in Pakistani Kashmir to provide surgery and medical treatment to ... in just 2 hours//. The unit comprises of a total ... unit was transported to Muzaffarabad, the Kashmir capital, in four ... to be a boon to the victims of the natural ...
... with obsessive-compulsive disorder (OCD) have received increased attention ... about whether OCD is characterized by deficits in ... ,Following from a recent study that ... a virtual computerized stove, researchers from the Department ...
... genetically modified mosquito has been created that wipe out natural ... of the world such as India and South Asia. ... the wild in an attempt to combat malaria that is ... ,A similar attempt was made in India in 1970s ...
... since ages, regarded as a mirror of the inner self. However, ... of a stroke and stroke-related death. // ,The study, ... non-invasive diagnostic tool using the eyes to determine whether people have ... study, people who have tiny lesions on the back of the ...
... chromosome 15 regulates inflammation according to scientists. Inflammation has ... disorders, including cancer, cardiovascular disease, diabetes, obesity, Alzheimer’s besides ... of the study said: “Practically every common disease involves ... Foundation for Biomedical Research (SFBR) in San Antonio., ...
Cached Medicine News:Health News:Lesions in the eyes may forecast a stroke 2
... comfortable pre-fabricated orthosis is designed for ... third humeral diaphyseal fractures. The lightweight ... soft tissue compression for optimal control ... motion of both shoulder and elbow ...
... AC Sport Brace is designed for the ... III acromioclavicular separations. Using a pre-inflated aircell, ... the acromioclavicular joint while supporting the arm ... with each AC Sport Brace for additional ...
The Humeral Stabilizing System is a terrific option for immobilization of stable humeral fractures, stablesupracondular fractures, and biceps/triceps repairs....
... Humerus Fracture Brace indications: , Nonoperative treatment ... Postoperative treatment of open humeral shaft fractures ... , After removal of internal or external ... Defects resulting from tumor growth , ...
Medicine Products: